News | August 12, 2021
Mangalam Drugs signs tech transfer agreement with Nigerian pharma company
Anti-malaria API facility will be operational in 15-18 months
Anti-malaria API facility will be operational in 15-18 months
It’s an AB-rated generic therapeutic version of Durezol
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
Subscribe To Our Newsletter & Stay Updated
